The health status of the CEE population has improved since 1990. However, only a few countries have closed the gap with the EU-15 countries. Inflammatory conditions might represent a significant disease burden in CEE countries; however, a thorough analysis and comparison to the EU-15 is difficult because of a shortage of good-quality data.

A129(anti-VEGF) were estimated based on prices established by Brazilian Drug Market Regulation Chamber. RESULTS: Nine studies were included: eight SR and one HTA. All reviews showed weak strength of recommendation and moderate to high quality of evidence. Sorafenib showed a median progression free-survival time around 6 months and was more effective than placebo, equally effective than interferon, and less effective than sunitinib. Patients who received sorafenib had a higher risk of suffering major adverse events.

In order to decrease the mortality due to breast cancer, the attendance rate of mammography screening programme should be increased. Orv. Hetil., 154(50), 1975-1983.

The occurrence of cervix cancer is outstandingly high in ZalaCounty

A739 adhered to, transparency issues remain. In contrast, clinical-effectiveness guidance is vague and compliance is very low which appears to be currently unrecognised as an issue. Therefore, a more stringent approach is needed when assessing PRO data within HTA, to ensure accurate measurement of treatment effectiveness to inform better decision making.